drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Patient-derived T cells genetically engineered to express a fully human anti‑CD19 scFv CAR with CD28–CD3ζ signaling domains; redirects T cells to recognize and kill CD19+ B cells, leading to depletion of malignant and normal B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a fully human anti‑CD19 scFv CAR with CD28 costimulatory and CD3ζ signaling domains. Binding to CD19 on B cells triggers MHC‑independent T‑cell activation, proliferation, cytokine release, and cytotoxic killing, resulting in depletion of CD19+ malignant and normal B cells.
drug_name
Autologous anti-CD19 CAR T cells (Hu19-CD828Z)
nct_id_drug_ref
NCT06364423